Recombinant SMAD4 antibody (AA 400-552)
Quick Overview for Recombinant SMAD4 antibody (AA 400-552) (ABIN7874725)
Target
See all SMAD4 AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 400-552
-
Purpose
- Recombinant SMAD4 Antibody
-
Purification
- Protein A/G affinity
-
Immunogen
- A recombinant partial protein sequence (within amino acids 400-552) from the human protein was used as the immunogen for the recombinant SMAD4 antibody.
-
Isotype
- IgG, kappa
-
-
-
-
Application Notes
- Optimal dilution of the recombinant SMAD4 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Aliquot the recombinant SMAD4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- SMAD4 (SMAD Family Member 4 (SMAD4))
-
Alternative Name
- SMAD4
-
Background
- Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF-beta family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80 % of cases of pancreatic adenocarcinoma, but rarely in endometrial (0 %), colorectal (0 %), ovarian (3 %), lung (0 %), breast (2 %) adenocarcinomas, and malignant melanoma (4 %). SMAD4is an important marker for confirming a diagnosis of pancreatic adenocarcinoma.
-
UniProt
- Q13485
-
Pathways
- Cell Division Cycle, Chromatin Binding, Autophagy
Target
-